Literature DB >> 25685386

Selective Use of (18)F-Fluorodeoxyglucose-Positron Emission Tomography and Computed Tomography in the Management of Metastatic Disease from Colorectal Cancer: Results from a regional centre.

Sadaf Jafferbhoy1, Adam Chambers1, James Mander1, Hugh Paterson1.   

Abstract

OBJECTIVES: Computed tomography (CT) scans are routinely used for primary staging and disease surveillance in patients with colorectal cancer. However, these scans have limited sensitivity in some organs and can only detect lesions with morphological changes, whereas (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG-PET) scans are able to detect areas of metabolic change before morphological changes appear. The aim of this study was to evaluate the impact of (18)F-FDG-PET/CT scans over conventional imaging during preoperative work-ups or follow-ups in a selected group of patients.
METHODS: This retrospective cohort study, which took place between July 2009 and May 2011, assessed 1,043 patient records from the South East Scotland Cancer Network colorectal cancer database. A total of 102 patients who underwent (18)F-FDG-PET/CT scans in addition to conventional imaging were included in the study. These patients had potentially resectable metastases, equivocal findings on CT scans and elevated carcinoembryonic antigen levels with negative conventional imaging.
RESULTS: Of the 102 patients included in the study, 22 underwent a preoperative (18)F-FDG-PET/CT scan and 80 underwent a follow-up 18F-FDG-PET/CT scan. In the preoperative scan group, the (18)F-FDG-PET/CT scan had a major impact on 16 patients (72.75%) and no impact on six patients (27.25%). In the follow-up scan group, the (18)F-FDG-PET/CT scan had a major impact on 51 (63.75%), a minor impact on four (5%), no impact on 22 (27.5%) and a negative impact on three (3.75%) patients.
CONCLUSION: The results of this study demonstrated that (18)F-FDG-PET/CT scans have a considerable effect on disease management when undertaken among indicated colorectal cancer patients.

Entities:  

Keywords:  18F Fluorodeoxyglucose; Cancer Staging; Carcinoembryonic Antigen; Colorectal Cancer; Metastases; Positron Emission Tomography; Recurrence; United Kingdom

Year:  2015        PMID: 25685386      PMCID: PMC4318607     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  20 in total

1.  Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.

Authors:  W A Bleeker; N H Mulder; J Hermans; R Otter; J T Plukker
Journal:  Br J Surg       Date:  2001-01       Impact factor: 6.939

2.  (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer.

Authors:  Long-Bang Chen; Jin-Long Tong; Hai-Zhu Song; Hong Zhu; Yu-Cai Wang
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

3.  Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.

Authors:  Yukishige Kyoto; Mitsuru Momose; Chisato Kondo; Michio Itabashi; Shingo Kameoka; Kiyoko Kusakabe
Journal:  Ann Nucl Med       Date:  2010-04-03       Impact factor: 2.668

Review 4.  Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet.

Authors:  I A Zealley; S J Skehan; J Rawlinson; G Coates; C Nahmias; S Somers
Journal:  Radiographics       Date:  2001-10       Impact factor: 5.333

5.  Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.

Authors:  T J M Ruers; B S Langenhoff; N Neeleman; G J Jager; S Strijk; Th Wobbes; F H M Corstens; W J G Oyen
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

6.  Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?

Authors:  L Staib; H Schirrmeister; S N Reske; H G Beger
Journal:  Am J Surg       Date:  2000-07       Impact factor: 2.565

7.  Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup.

Authors:  E E Zervos; B D Badgwell; W E Burak; M W Arnold; E W Martin
Journal:  Surgery       Date:  2001-10       Impact factor: 3.982

8.  Does positron emission tomography change management in primary rectal cancer? A prospective assessment.

Authors:  Alexander G Heriot; Rodney J Hicks; Elizabeth G P Drummond; Jamie Keck; John Mackay; Frank Chen; Victor Kalff
Journal:  Dis Colon Rectum       Date:  2004-02-25       Impact factor: 4.585

9.  Results of R0 resection for colorectal liver metastases associated with extrahepatic disease.

Authors:  Dominique Elias; Lucas Sideris; Marc Pocard; Jean-Francois Ouellet; Valérie Boige; Philippe Lasser; Jean-Pierre Pignon; Michel Ducreux
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

10.  Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy.

Authors:  R A Graham; S Wang; P J Catalano; D G Haller
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

View more
  2 in total

1.  (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in the Management of Metastatic Colorectal Cancer: Are we there yet?

Authors:  Khalid Al-Naamani; Siham Al-Sinani
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

2.  Combined Positron Emission Tomography and Computed Tomography: Option or necessity?

Authors:  Naima K Al-Bulushi
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.